Stock BCTX BRIACELL THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News BriaCell Therapeutics Corp. Nasdaq

Equities

BCTX

CA1079301091

Real-time Estimate Cboe BZX
Other stock markets
 01:32:30 2024-05-03 pm EDT 		5-day change 1st Jan Change
2.265 USD +1.12% Intraday chart for BriaCell Therapeutics Corp. +5.99% -60.68%
Apr. 24 BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting MT
Apr. 10 BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting
MT
BriaCell Announces Oral and Poster Presentations at ASCO 2024
AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer
CI
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR
MT
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
AQ
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K
PU
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
CI
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
AQ
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference
MT
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
AQ
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
AQ
BriaCell Announces Strong Clinical Data in Breast Cancer Patients
MT
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
CI
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
AQ
Toronto Stocks Rally; Precision Drilling Rises on 4Q Profit Growth
DJ
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
AQ
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing
CI
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
AQ
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCT Stock
  4. BCTX Stock
  5. News BriaCell Therapeutics Corp.